ArticleGenome biology2026
DNA damaging properties of G-quadruplex ligand QN-302 are potentiated by the DNA repair inhibitor Olaparib and mitigated by the molecular helicase PhpC.
Article in Genome biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AGAPE (Computational G‑Quadruplex Stabilization Prediction): The First Machine Learning Workflow for G‑Quadruplex Stabilization Prediction.ACS omega · 2026Article
- DNA damaging properties of G-quadruplex ligand QN-302 are potentiated by the DNA repair inhibitor Olaparib and mitigated by the molecular helicase PhpC.Genome biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundQN-302 is a tetra-substituted naphthalene diimide (NDI) designed to bind G-quadruplex (G4) DNA and is in a phase 1 clinical trial for pancreatic ductal adenocarcinoma (PDAC) and other solid tumors. The mechanistic basis of its anticancer activity remains to be fully understood.
resultsUsing in vitro fluorescence quenching and FRET-melting assays together with cell-based in situ click imaging and γH2AX immunodetection, we show that QN-302 engages cellular G4s and triggers G4-associated DNA damage in human cancer cells. In HeLa cells, short exposures increase G4 foci and double strand break (DSB) markers, whereas pre-incubation with the G4-disruptor PhpC reduces both, supporting a G4-dependent mechanism. In PDAC (MIA PaCa-2) cells, QN-302's antiproliferative activity synergizes with the PARP1 inhibitor Olaparib. Combination treatment produces supra-additive increases in γH2AX foci and yields Bliss synergy across multiple dose pairs, consistent with chemically induced synthetic lethality.
conclusionsQN-302 induces G4-mediated DNA damage that underpins potent antiproliferative effects. Inhibition of DNA repair with Olaparib augments this activity, whereas pharmacological G4 destabilization with PhpC attenuates it. These findings support a defined mechanism of action for QN-302 and provide a rationale for clinical combination strategies in PDAC and potentially other cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.